Description: Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Description: A number of stocks jumped in the afternoon session after a report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies.

Description: Thinking about whether Incyte might be worth more than its current price tag? You are not alone, as many investors are asking the same question right now. The stock has surged 46.8% year-to-date, climbing 42.3% over the past 12 months, despite taking a minor 2.0% dip in the last week. Recent headlines have centered on Incyte’s expanding drug pipeline and positive updates around new FDA approvals, fueling optimism and catching the attention of analysts and shareholders. These developments are...

Description: When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Description: WILMINGTON, Del., November 19, 2025--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of December:

Description: MORGES, Switzerland, November 17, 2025--Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)

Description: Incyte has delivered better returns than the broader market over the past year, and analysts view the stock’s outlook with measured optimism.

Description: Incyte (INCY) has delivered a steady performance lately, as investors track the company’s moderate growth trends and recent market movements. Over the past month, shares have climbed 28%, indicating renewed attention from the market. See our latest analysis for Incyte. After surging nearly 28% over the past month, Incyte’s share price is showing real momentum as investors absorb recent developments and weigh the company’s moderate but persistent growth. In fact, the company’s 55.7%...

Description: Ocular Therapeutix stock is one stock that just reached the mark, now earning a score of 81. Is Ocular Therapeutix Stock A Buy? Ocular Therapeutix stock is currently trading below its 50-day moving average, but rallying with the sector.

Description: A Relative Strength Rating upgrade for Halozyme Therapeutics shows improving technical performance. Will it continue?

Description: Wondering whether Incyte is priced right, or if the market is missing something? You're not alone. This is one biotech that has investors talking about value. The stock has surged 17.2% in just the past week, racking up a 52.0% gain year-to-date and rising 30.6% over the last twelve months. This has prompted many to reconsider its growth potential and risk profile. Much of this momentum came on the heels of positive headlines around recent product pipeline updates and strategic partnerships...

Description: WILMINGTON, Del., November 06, 2025--Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema

Description: Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company’s preliminary estimates, and potentially int

Description: Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milestones plus royalties on net sa

Description: We recently published Wall Street Can’t Keep up With These 10 Crushing Stocks; 6 at Fresh Record Highs. Incyte Corp. (NASDAQ:INCY) is one of the best-performing on Monday. Incyte extended its winning streak to a third straight day to hit a new all-time high as investors took heart from an investment firm’s bullish coverage for […]

Description: The Morning Bull - US Market Morning Update Tuesday, Nov, 4 2025 US stock futures are sliding premarket as investors digest hawkish signals from the Federal Reserve and ongoing signs of strain in the manufacturing sector. With Fed officials making it clear that a December rate cut is not guaranteed, and manufacturing data painting a mixed, uncertain picture, market sentiment is becoming more cautious as investors weigh the impact of elevated yields and weaker production on broader economic...

Description: Incyte’s third quarter saw revenue and profit surpass Wall Street’s expectations, yet the market responded negatively. Management identified robust demand for key drugs Jakafi and Opzelura, alongside the launch traction of Niktimvo, as major contributors to the quarter’s strong operational performance. CEO William Meury emphasized the company’s ongoing cost discipline and strategic investment in core R&D programs. He noted, “Our job right now is to keep [the fundamentals] that way and to identif

Description: WILMINGTON, Del., November 03, 2025--Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

Description: Incyte Corp (INCY) reports a 20% revenue increase, raises full-year guidance, and outlines strategic shifts amid competitive challenges.

Description: The United States vitiligo market is projected to grow from $202.87 million in 2024 to $320.71 million by 2033, driven by a 5.22% CAGR from 2025. This growth is fueled by increasing awareness, innovative therapies, and improved diagnostic methods. Key treatment advancements include biologics, phototherapy, and topical solutions. Challenges include limited curative options and high treatment costs. States like California, New York, Texas, and Florida lead due to strong healthcare infrastructure.

Description: WILMINGTON, Del., October 30, 2025--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November:

Description: Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share was 38% above analysts’ consensus estimates.

Description: Incyte Corporation recently reported third-quarter 2025 earnings well above analyst expectations, with revenue rising to US$1.37 billion and net income reaching US$424.17 million, while also presenting strong late-stage clinical trial results for key immunology and oncology assets. These developments highlight both robust demand for Incyte's current products and growing investor confidence in the company's pipeline, particularly as it prepares for new product launches and international...

Description: Incyte stock edged down Tuesday despite widely beating third-quarter forecasts, on its light 2025 outlook.

Description: This biotech under $100 looks like a growth opportunity worth grabbing before it soars.

Description: Incyte Corporation (NASDAQ:INCY) is one of the most profitable biotech stocks to buy. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) on October 22, setting a price target of $104. However, J.P. Morgan analyst Jessica Fye reiterated a Hold rating on Incyte Corporation (NASDAQ:INCY) on October 20. Fye […]

Description: Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 4.2% in the morning session after the company reported underwhelming third-quarter 2025 financial results.

Description: Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.

Description: William Meury: Thank you, Alexis, and good morning, everyone. In terms of the core business, my assessment has reinforced my confidence in the growth potential of our key products. The fundamentals around Jakafi, Opzelura, and our hematology business, Naktinvo and Monjuvi, namely, remain strong.

Description: While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: Incyte (INCY) delivered earnings and revenue surprises of +36.14% and +8.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share was 38% above analysts’ consensus estimates.

Description: WILMINGTON, Del. AP) — Incyte Corp. INCY) on Tuesday reported third-quarter earnings of $424.2 million.

Description: WILMINGTON, Del., October 28, 2025--Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates

Description: ANIP's rising Cortrophin Gel sales and new rare disease products, along with generic and other segments, could power another earnings beat this quarter.

Description: WILMINGTON, Del. & CINCINNATI, October 27, 2025--Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System

Description: Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings this Tuesday morning. Here’s what you need to know.

Description: New data from the Phase 3 BRAVE-AA-PEDS trial highlights baricitinib’s strong performance in adolescents facing severe alopecia areata. Incyte (INCY) and Eli Lilly now plan to pursue global approvals for expanded use based on these results. See our latest analysis for Incyte. Incyte’s momentum has really picked up this year thanks to positive trial results and recent pipeline updates, such as its advances in atopic dermatitis and cancer immunotherapies. The stock’s strong 31% share price...

Description: WILMINGTON, Del., October 25, 2025--Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis

Description: INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.

Description: Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Description: New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. These 52-week results from the BRAVE-AA-PEDS trial – the largest Phase 3 study of its kind – will be presented at the 2025 Fall Clinical Dermatology (FCD) Conference, taking place Oct. 23-26 in Las Vegas.1

Description: Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Incyte will release its third-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

Description: If you've been thinking about what to do with your Incyte shares, or whether now is a smart time to jump in, you’re not alone. The stock has been on the move lately, catching the attention of both careful investors and opportunists alike. In the past week alone, Incyte has climbed 3.4%, adding to a year-to-date rise of 25.9%. Over the last year, shareholders have enjoyed a 34.2% return, a marked turnaround from its rather sluggish five-year performance, which is still down 3.2%. That kind of...

Description: Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Description: WILMINGTON, Del., October 19, 2025--Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced CRC and KRAS G12D Inhibitor in Advanced PDAC